NCT02792517 - Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 12, 2016

Primary Completion Date

September 9, 2016

Study Completion Date

September 9, 2016

Conditions

Headache, Migraine

Interventions

DRUG

Erenumab

A single dose of erenumab administered in the abdomen.

DRUG

Ethynil Estradiol/Norgestimate Oral Contraceptive

Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.

Trial Locations (4)

53704

Research Site, Madison

75247

Research Site, Dallas

90630

Research Site, Cypress

92801

Research Site, Anaheim